Regeneron Pharmaceuticals, Inc. (REGN)

957.00 +19.39 (+2.07%) 收市：04:00PM EDT

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

版塊: Healthcare
行業: Biotechnology
全職員工: 13,677

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	8.18M	無	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	7.76M	無	1960
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1.68M	21.37M	1959
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply	2.01M	10.67M	1973
Mr. Christopher R. Fenimore CPA	Senior VP of Finance & CFO	無	無	1971
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	無	無	無
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer	無	無	無
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	無	無	無
Mr. Joseph J. LaRosa	Executive VP, General Counsel & Secretary	1.75M	23.23M	1959
Ms. Melissa Lozner	Senior VP & Chief Compliance Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

公司管治

截至 2024年5月1日 止，Regeneron Pharmaceuticals, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：10；董事會：10；股東權利：10；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。